{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:06:26Z","timestamp":1793048786852,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009160","name":"Universit\u00e9 Toulouse III - Paul Sabatier","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009160","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>The present review will examine bone disease in mastocytosis, analyze the existing literature on its management, and propose a strategy for osteoporosis treatment in systemic mastocytosis. This strategy is based on both the available scientific evidence and the experience gained at our expert center (CEREMAST).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Systemic mastocytosis is a rare disorder, primarily affecting the bone and leading to osteoporosis, bone pain, and bone structural abnormalities. While traditionally described in indolent systemic mastocytosis, bone involvement is also observed in bone marrow mastocytosis. The true prevalence of systemic mastocytosis is likely underreported, highlighting the importance for clinicians to be familiar with the condition, particularly in cases of osteoporosis. Osteoporosis management typically involves bisphosphonates, with potential benefits from combining them with specific treatments like interferon in severe osteoporosis with vertebral fractures. The potential of new mast cell-targeting molecules to treat bone involvement needs to be demonstrated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>This review provides a guide for osteoporosis and bone pain management in systemic mastocytosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11914-025-00901-w","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T02:15:37Z","timestamp":1739412937000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Management of Bone Health in Adult Mastocytosis"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4293-8596","authenticated-orcid":false,"given":"Yannick","family":"Degbo\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coralie","family":"Nezzar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Alary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masson","family":"Ma\u00ebva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Bulai Livideanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Laroche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"issue":"7","key":"901_CR1","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/s0145-2126(01)00021-2","volume":"25","author":"HP Horny","year":"2001","unstructured":"Horny HP, Valent P. Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res. 2001;25(7):543\u201351. https:\/\/doi.org\/10.1016\/s0145-2126(01)00021-2.","journal-title":"Leuk Res"},{"issue":"4","key":"901_CR2","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/ajh.26118","volume":"96","author":"A Pardanani","year":"2021","unstructured":"Pardanani A. Systemic mastocytosis in adults: 2021 update on diagnosis, risk stratification and management. Am J Hematol. 2021;96(4):508\u201325. https:\/\/doi.org\/10.1002\/ajh.26118.","journal-title":"Am J Hematol"},{"issue":"8","key":"901_CR3","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1016\/j.jaip.2022.03.007","volume":"10","author":"P Valent","year":"2022","unstructured":"Valent P, Hartmann K, Schwaab J, Alvarez-Twose I, Brockow K, Bonadonna P, et al. Personalized management strategies in mast cell disorders: ECNM-AIM user\u2019s guide for Daily Clinical Practice. J Allergy Clin Immunol Pract. 2022;10(8):1999\u20132012. https:\/\/doi.org\/10.1016\/j.jaip.2022.03.007. e6.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"901_CR4","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s00256-012-1374-9","volume":"41","author":"J Fritz","year":"2012","unstructured":"Fritz J, Fishman EK, Carrino JA, Horger MS. Advanced imaging of skeletal manifestations of systemic mastocytosis. Skeletal Radiol. 2012;41(8):887\u201397. https:\/\/doi.org\/10.1007\/s00256-012-1374-9.","journal-title":"Skeletal Radiol"},{"key":"901_CR5","doi-asserted-by":"publisher","first-page":"100693","DOI":"10.1016\/j.blre.2020.100693","volume":"45","author":"K Ozturk","year":"2021","unstructured":"Ozturk K, Cayci Z, Gotlib J, Akin C, George TI, Ustun C. Non-hematologic diagnosis of systemic mastocytosis: collaboration of radiology and pathology. Blood Rev. 2021;45:100693. https:\/\/doi.org\/10.1016\/j.blre.2020.100693.","journal-title":"Blood Rev"},{"key":"901_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03826-4","author":"P Riffel","year":"2019","unstructured":"Riffel P, Jawhar M, Gawlik K, Schwaab J, Michaely HJ, Metzgeroth G, et al. Magnetic resonance imaging reveals distinct bone marrow patterns in indolent and advanced systemic mastocytosis. Ann Hematol. 2019. https:\/\/doi.org\/10.1007\/s00277-019-03826-4.","journal-title":"Ann Hematol"},{"issue":"10","key":"901_CR7","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1136\/ard.2009.124511","volume":"69","author":"S Barete","year":"2010","unstructured":"Barete S, Assous N, de Gennes C, Grandpeix C, Feger F, Palmerini F, et al. Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann Rheum Dis. 2010;69(10):1838\u201341. https:\/\/doi.org\/10.1136\/ard.2009.124511.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"901_CR8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/pde.12291","volume":"31","author":"M Barnes","year":"2014","unstructured":"Barnes M, Van L, DeLong L, Lawley LP. Severity of cutaneous findings predict the presence of systemic symptoms in pediatric maculopapular cutaneous mastocytosis. Pediatr Dermatol. 2014;31(3):271\u20135. https:\/\/doi.org\/10.1111\/pde.12291.","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"901_CR9","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/00005792-198811000-00001","volume":"67","author":"WD Travis","year":"1988","unstructured":"Travis WD, Li CY, Bergstralh EJ, Yam LT, Swee RG. Systemic mast cell disease. Analysis of 58 cases and literature review. Med (Baltim). 1988;67(6):345\u201368.","journal-title":"Med (Baltim)"},{"key":"901_CR10","doi-asserted-by":"publisher","unstructured":"Bouvard B, Pascaretti-Grizon F, Legrand E, Lavigne C, Audran M, Chappard D. Bone lesions in systemic mastocytosis: bone histomorphometry and histopathological mechanisms. Morphologie. 2020;S1286011520300059. https:\/\/doi.org\/10.1016\/j.morpho.2020.01.004.","DOI":"10.1016\/j.morpho.2020.01.004"},{"issue":"8","key":"901_CR11","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1007\/s00198-013-2305-x","volume":"24","author":"S Seitz","year":"2013","unstructured":"Seitz S, Barvencik F, Koehne T, Priemel M, Pogoda P, Semler J, et al. Increased osteoblast and osteoclast indices in individuals with systemic mastocytosis. Osteoporos Int. 2013;24(8):2325\u201334. https:\/\/doi.org\/10.1007\/s00198-013-2305-x.","journal-title":"Osteoporos Int"},{"issue":"1","key":"901_CR12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.bone.2003.08.007","volume":"34","author":"P Lesclous","year":"2004","unstructured":"Lesclous P, Guez D, Baroukh B, Vignery A, Saffar JL. Histamine participates in the early phase of trabecular bone loss in ovariectomized rats. Bone. 2004;34(1):91\u20139. https:\/\/doi.org\/10.1016\/j.bone.2003.08.007.","journal-title":"Bone"},{"issue":"1","key":"901_CR13","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/leu.2015.176","volume":"30","author":"A Mayado","year":"2016","unstructured":"Mayado A, Teodosio C, Garcia-Montero AC, Matito A, Rodriguez-Caballero A, Morgado JM, et al. Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression. Leukemia. 2016;30(1):124\u201330. https:\/\/doi.org\/10.1038\/leu.2015.176.","journal-title":"Leukemia"},{"key":"901_CR14","doi-asserted-by":"publisher","unstructured":"Rabenhorst A, Christopeit B, Leja S, Gerbaulet A, Kleiner S, Forster A et al. Serum levels of bone cytokines are increased in indolent systemic mastocytosis associated with osteopenia or osteoporosis. J Allergy Clin Immunol. 2013;132(5):1234-7 e7. https:\/\/doi.org\/10.1016\/j.jaci.2013.06.019","DOI":"10.1016\/j.jaci.2013.06.019"},{"issue":"5","key":"901_CR15","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1016\/j.jaip.2023.02.007","volume":"11","author":"TA Rama","year":"2023","unstructured":"Rama TA, Henriques AF, Matito A, Jara-Acevedo M, Caldas C, Mayado A, et al. Bone and cytokine markers Associated with Bone Disease in systemic mastocytosis. J Allergy Clin Immunol Pract. 2023;11(5):1536\u201347. https:\/\/doi.org\/10.1016\/j.jaip.2023.02.007.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"901_CR16","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1038\/s41467-021-22754-4","volume":"12","author":"DK Kim","year":"2021","unstructured":"Kim DK, Bandara G, Cho YE, Komarow HD, Donahue DR, Karim B, et al. Mastocytosis-derived extracellular vesicles deliver miR-23a and miR-30a into pre-osteoblasts and prevent osteoblastogenesis and bone formation. Nat Commun. 2021;12(1):2527. https:\/\/doi.org\/10.1038\/s41467-021-22754-4.","journal-title":"Nat Commun"},{"issue":"23","key":"901_CR17","first-page":"1611","volume":"44","author":"S de Seze","year":"1968","unstructured":"de Seze S, Hioco D, Matrajt H, Tun Chot S. [Osteoporosis and mastocytosis. Apropos of 2 cases]. Sem Hop. 1968;44(23):1611\u20135.","journal-title":"Sem Hop"},{"issue":"9","key":"901_CR18","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/s0046-8177(81)80084-6","volume":"12","author":"MD Fallon","year":"1981","unstructured":"Fallon MD, Whyte MP, Teitelbaum SL. Systemic mastocytosis associated with generalized osteopenia. Histopathological characterization of the skeletal lesion using undecalcified bone from two patients. Hum Pathol. 1981;12(9):813\u201320. https:\/\/doi.org\/10.1016\/s0046-8177(81)80084-6.","journal-title":"Hum Pathol"},{"issue":"6","key":"901_CR19","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00223-021-00887-4","volume":"109","author":"M Gehlen","year":"2021","unstructured":"Gehlen M, Schmidt N, Pfeifer M, Balasingam S, Schwarz-Eywill M, Maier A, et al. Osteoporosis caused by systemic mastocytosis: prevalence in a cohort of 8392 patients with osteoporosis. Calcif Tissue Int. 2021;109(6):685\u201395. https:\/\/doi.org\/10.1007\/s00223-021-00887-4.","journal-title":"Calcif Tissue Int"},{"key":"901_CR20","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.bone.2017.09.005","volume":"105","author":"Y Degboe","year":"2017","unstructured":"Degboe Y, Eischen M, Nigon D, Apoil PA, Mailhol C, Tournier E, et al. Prevalence and risk factors for fragility fracture in systemic mastocytosis. Bone. 2017;105:219\u201325. https:\/\/doi.org\/10.1016\/j.bone.2017.09.005.","journal-title":"Bone"},{"issue":"5","key":"901_CR21","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.jaip.2024.02.021","volume":"12","author":"Y Degboe","year":"2024","unstructured":"Degboe Y, Severino-Freire M, Couture G, Apoil PA, Gaudenzio N, Hermine O, et al. The prevalence of osteoporosis is low in adult cutaneous mastocytosis patients. J Allergy Clin Immunol Pract. 2024;12(5):1306\u201312. https:\/\/doi.org\/10.1016\/j.jaip.2024.02.021.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"901_CR22","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.jaci.2009.05.003","volume":"124","author":"L Escribano","year":"2009","unstructured":"Escribano L, Alvarez-Twose I, Sanchez-Munoz L, Garcia-Montero A, Nunez R, Almeida J, et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on mastocytosis in a series of 145 patients. J Allergy Clin Immunol. 2009;124(3):514\u201321. https:\/\/doi.org\/10.1016\/j.jaci.2009.05.003.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"901_CR23","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.bone.2011.07.004","volume":"49","author":"M Rossini","year":"2011","unstructured":"Rossini M, Zanotti R, Bonadonna P, Artuso A, Caruso B, Schena D, et al. Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. Bone. 2011;49(4):880\u20135. https:\/\/doi.org\/10.1016\/j.bone.2011.07.004.","journal-title":"Bone"},{"issue":"6","key":"901_CR24","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/j.jaci.2014.05.003","volume":"134","author":"E van der Veer","year":"2014","unstructured":"van der Veer E, Arends S, van der Hoek S, Versluijs JB, de Monchy JG, Oude Elberink JN, et al. Predictors of new fragility fractures after diagnosis of indolent systemic mastocytosis. J Allergy Clin Immunol. 2014;134(6):1413\u201321. https:\/\/doi.org\/10.1016\/j.jaci.2014.05.003.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"901_CR25","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/j.1398-9995.2011.02780.x","volume":"67","author":"E van der Veer","year":"2012","unstructured":"van der Veer E, van der Goot W, de Monchy JG, Kluin-Nelemans HC, van Doormaal JJ. High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis. Allergy. 2012;67(3):431\u20138. https:\/\/doi.org\/10.1111\/j.1398-9995.2011.02780.x.","journal-title":"Allergy"},{"issue":"7","key":"901_CR26","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and Histiocytic\/Dendritic neoplasms. Leukemia. 2022;36(7):1703\u201319. https:\/\/doi.org\/10.1038\/s41375-022-01613-1.","journal-title":"Leukemia"},{"issue":"11","key":"901_CR27","doi-asserted-by":"publisher","first-page":"e646","DOI":"10.1097\/HS9.0000000000000646","volume":"5","author":"P Valent","year":"2021","unstructured":"Valent P, Akin C, Hartmann K, Alvarez-Twose I, Brockow K, Hermine O, et al. Updated diagnostic criteria and classification of mast cell disorders: a Consensus proposal. Hemasphere. 2021;5(11):e646. https:\/\/doi.org\/10.1097\/HS9.0000000000000646.","journal-title":"Hemasphere"},{"key":"901_CR28","volume-title":"Characteristics and risk factors Associated with Fragility fractures in patients with primary and idiopathic mast cell activation syndromes [abstract]","author":"A Ramos Lisbona","year":"2023","unstructured":"Ramos Lisbona A, Carpio Astudillo K, Skrabski F, Prieto Garc\u00eda A, Castrejon I, Rivera J, et al. Characteristics and risk factors Associated with Fragility fractures in patients with primary and idiopathic mast cell activation syndromes [abstract]. Volume 75. Hoboken, NJ: Arthritis & rheumatology; 2023. ((suppl 9))."},{"issue":"6","key":"901_CR29","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/BF01622200","volume":"4","author":"JA Kanis","year":"1994","unstructured":"Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int. 1994;4(6):368\u201381. https:\/\/doi.org\/10.1007\/BF01622200.","journal-title":"Osteoporos Int"},{"issue":"4","key":"901_CR30","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1007\/BF01623782","volume":"7","author":"JA Kanis","year":"1997","unstructured":"Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D. Guidelines for diagnosis and management of osteoporosis. Osteoporos Int. 1997;7(4):390\u2013406. https:\/\/doi.org\/10.1007\/BF01623782.","journal-title":"Osteoporos Int"},{"issue":"6","key":"901_CR31","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s00198-019-04918-7","volume":"30","author":"Y Degboe","year":"2019","unstructured":"Degboe Y, Eischen M, Apoil PA, Mailhol C, Dubreuil P, Hermine O, et al. Higher prevalence of vertebral fractures in systemic mastocytosis, but not in cutaneous mastocytosis and idiopathic mast cell activation syndrome. Osteoporos Int. 2019;30(6):1235\u201341. https:\/\/doi.org\/10.1007\/s00198-019-04918-7.","journal-title":"Osteoporos Int"},{"issue":"1","key":"901_CR32","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s00223-016-0198-3","volume":"100","author":"A Artuso","year":"2017","unstructured":"Artuso A, Caimmi C, Tripi G, Viapiana O, Bonifacio M, Idolazzi L, et al. Longitudinal evaluation of bone Mineral density and bone metabolism markers in patients with indolent systemic mastocytosis without osteoporosis. Calcif Tissue Int. 2017;100(1):40\u20136. https:\/\/doi.org\/10.1007\/s00223-016-0198-3.","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"901_CR33","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/cea.12627","volume":"46","author":"C Bulai Livideanu","year":"2016","unstructured":"Bulai Livideanu C, Apoil PA, Lepage B, Eischen M, Laurent C, Laharrague P, et al. Bone marrow tryptase as a possible diagnostic criterion for adult systemic mastocytosis. Clin Exp Allergy. 2016;46(1):133\u201341. https:\/\/doi.org\/10.1111\/cea.12627.","journal-title":"Clin Exp Allergy"},{"issue":"8","key":"901_CR34","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1007\/s00198-016-3539-1","volume":"27","author":"M Rossini","year":"2016","unstructured":"Rossini M, Zanotti R, Orsolini G, Tripi G, Viapiana O, Idolazzi L, et al. Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis. Osteoporos Int. 2016;27(8):2411\u201321. https:\/\/doi.org\/10.1007\/s00198-016-3539-1.","journal-title":"Osteoporos Int"},{"issue":"4","key":"901_CR35","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1159\/000063858","volume":"128","author":"TC Theoharides","year":"2002","unstructured":"Theoharides TC, Boucher W, Spear K. Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol. 2002;128(4):344\u201350. https:\/\/doi.org\/10.1159\/000063858.","journal-title":"Int Arch Allergy Immunol"},{"issue":"6","key":"901_CR36","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/leu.2015.24","volume":"29","author":"M Arock","year":"2015","unstructured":"Arock M, Sotlar K, Akin C, Broesby-Olsen S, Hoermann G, Escribano L, et al. KIT mutation analysis in mast cell neoplasms: recommendations of the European competence network on mastocytosis. Leukemia. 2015;29(6):1223\u201332. https:\/\/doi.org\/10.1038\/leu.2015.24.","journal-title":"Leukemia"},{"issue":"2","key":"901_CR37","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jmoldx.2010.10.004","volume":"13","author":"T Kristensen","year":"2011","unstructured":"Kristensen T, Vestergaard H, Moller MB. Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. J Mol Diagn. 2011;13(2):180\u20138. https:\/\/doi.org\/10.1016\/j.jmoldx.2010.10.004.","journal-title":"J Mol Diagn"},{"issue":"3","key":"901_CR38","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/rheumatology\/36.3.393","volume":"36","author":"A Marshall","year":"1997","unstructured":"Marshall A. The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis. Rheumatology. 1997;36(3):393\u20136. https:\/\/doi.org\/10.1093\/rheumatology\/36.3.393.","journal-title":"Rheumatology"},{"issue":"6","key":"901_CR39","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1136\/ard.2004.029116","volume":"64","author":"AY Lim","year":"2005","unstructured":"Lim AY, Ostor AJ, Love S, Crisp AJ. Systemic mastocytosis: a rare cause of osteoporosis and its response to bisphosphonate treatment. Ann Rheum Dis. 2005;64(6):965\u20136. https:\/\/doi.org\/10.1136\/ard.2004.029116.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"901_CR40","doi-asserted-by":"publisher","first-page":"3557","DOI":"10.1016\/j.jaip.2020.06.054","volume":"8","author":"MC Onnes","year":"2020","unstructured":"Onnes MC, van Doormaal JJ, van der Veer E, Versluijs JB, Arends S, Oude Elberink HNG. Fracture risk reduction by bisphosphonates in Mastocytosis? J Allergy Clin Immunol Pract. 2020;8(10):3557\u201364. https:\/\/doi.org\/10.1016\/j.jaip.2020.06.054.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"901_CR41","doi-asserted-by":"publisher","unstructured":"Rossini M, Zanotti R, Viapiana O, Tripi G, Idolazzi L, Biondan M et al. Zoledronic acid in osteoporosis secondary to mastocytosis. Am J Med. 2014;127(11):1127 e1- e4. https:\/\/doi.org\/10.1016\/j.amjmed.2014.06.015","DOI":"10.1016\/j.amjmed.2014.06.015"},{"key":"901_CR42","doi-asserted-by":"publisher","unstructured":"Nezzar C, Alary P, Ruyssen-Witrand A, Couture G, Severino-Freire M, Laroche M, et al. Management of osteoporosis in patients with systemic mastocytosis: a monocentric expert centre experience. Ann Rheum Dis. 2023;82(Suppl 1). https:\/\/doi.org\/10.1136\/annrheumdis-2023-eular.3302.","DOI":"10.1136\/annrheumdis-2023-eular.3302"},{"issue":"6","key":"901_CR43","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00223-017-0241-z","volume":"100","author":"G Orsolini","year":"2017","unstructured":"Orsolini G, Gavioli I, Tripi G, Viapiana O, Gatti D, Idolazzi L, et al. Denosumab for the treatment of mastocytosis-related osteoporosis: a Case Series. Calcif Tissue Int. 2017;100(6):595\u20138. https:\/\/doi.org\/10.1007\/s00223-017-0241-z.","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"901_CR44","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/jbmr.251","volume":"26","author":"R Eastell","year":"2011","unstructured":"Eastell R, Christiansen C, Grauer A, Kutilek S, Libanati C, McClung MR, et al. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Min Res. 2011;26(3):530\u20137. https:\/\/doi.org\/10.1002\/jbmr.251.","journal-title":"J Bone Min Res"},{"issue":"2","key":"901_CR45","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","volume":"33","author":"SR Cummings","year":"2018","unstructured":"Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JB, McClung M, et al. Vertebral fractures after discontinuation of Denosumab: a Post Hoc Analysis of the Randomized Placebo-controlled FREEDOM trial and its extension. J Bone Min Res. 2018;33(2):190\u20138. https:\/\/doi.org\/10.1002\/jbmr.3337.","journal-title":"J Bone Min Res"},{"issue":"2","key":"901_CR46","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s10067-006-0369-0","volume":"26","author":"M Laroche","year":"2007","unstructured":"Laroche M, Bret J, Brouchet A, Mazi\u00e8res B. Clinical and densitometric efficacy of the association of interferon alpha and pamidronate in the treatment of osteoporosis in patients with systemic mastocytosis. Clin Rheumatol. 2007;26(2):242\u20133. https:\/\/doi.org\/10.1007\/s10067-006-0369-0.","journal-title":"Clin Rheumatol"},{"issue":"8","key":"901_CR47","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.amjmed.2011.02.038","volume":"124","author":"M Laroche","year":"2011","unstructured":"Laroche M, Livideanu C, Paul C, Cantagrel A. Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis. Am J Med. 2011;124(8):776\u20138. https:\/\/doi.org\/10.1016\/j.amjmed.2011.02.038.","journal-title":"Am J Med"},{"issue":"9","key":"901_CR48","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1093\/rheumatology\/35.9.898","volume":"35","author":"T Lehmann","year":"1996","unstructured":"Lehmann T, Beyeler C, Lammle B, Hunziker T, Vock P, Olah AJ, et al. Severe osteoporosis due to systemic mast cell disease: successful treatment with interferon alpha-2B. Br J Rheumatol. 1996;35(9):898\u2013900. https:\/\/doi.org\/10.1093\/rheumatology\/35.9.898.","journal-title":"Br J Rheumatol"},{"issue":"1","key":"901_CR49","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/BF00663015","volume":"72","author":"R Weide","year":"1996","unstructured":"Weide R, Ehlenz K, Lorenz W, Walthers E, Klausmann M, Pfluger KH. Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b. Ann Hematol. 1996;72(1):41\u20133. https:\/\/doi.org\/10.1007\/BF00663015.","journal-title":"Ann Hematol"},{"issue":"12","key":"901_CR50","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/j.1365-2362.2008.02047.x","volume":"38","author":"NM Kushnir-Sukhov","year":"2008","unstructured":"Kushnir-Sukhov NM, Brittain E, Scott L, Metcalfe DD. Clinical correlates of blood serotonin levels in patients with mastocytosis. Eur J Clin Invest. 2008;38(12):953\u20138. https:\/\/doi.org\/10.1111\/j.1365-2362.2008.02047.x.","journal-title":"Eur J Clin Invest"},{"issue":"6","key":"901_CR51","first-page":"E849","volume":"20","author":"S Wirz","year":"2017","unstructured":"Wirz S, Molderings GJ. A practical guide for treatment of Pain in patients with systemic mast cell activation disease. Pain Physician. 2017;20(6):E849\u201361.","journal-title":"Pain Physician"},{"key":"901_CR52","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/1752-1947-4-193","volume":"4","author":"AM Edwards","year":"2010","unstructured":"Edwards AM, Hagberg H. Oral and inhaled sodium cromoglicate in the management of systemic mastocytosis: a case report. J Med Case Rep. 2010;4:193. https:\/\/doi.org\/10.1186\/1752-1947-4-193.","journal-title":"J Med Case Rep"},{"issue":"2","key":"901_CR53","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s00330-017-5019-1","volume":"28","author":"V Bousson","year":"2018","unstructured":"Bousson V, Leturcq T, Ea HK, Hauger O, Mehsen-Cetre N, Hamze B, et al. An open-label, prospective, observational study of the efficacy of bisphosphonate therapy for painful osteoid osteoma. Eur Radiol. 2018;28(2):478\u201386. https:\/\/doi.org\/10.1007\/s00330-017-5019-1.","journal-title":"Eur Radiol"},{"issue":"35","key":"901_CR54","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.2017.75.4614","volume":"35","author":"C Van Poznak","year":"2017","unstructured":"Van Poznak C, Somerfield MR, Barlow WE, Biermann JS, Bosserman LD, Clemons MJ, et al. Role of bone-modifying agents in metastatic breast Cancer: an American Society of Clinical Oncology-Cancer Care Ontario focused Guideline Update. J Clin Oncol. 2017;35(35):3978\u201386. https:\/\/doi.org\/10.1200\/JCO.2017.75.4614.","journal-title":"J Clin Oncol"},{"issue":"4","key":"901_CR55","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1097\/00000421-199408000-00009","volume":"17","author":"PA Johnstone","year":"1994","unstructured":"Johnstone PA, Mican JM, Metcalfe DD, DeLaney TF. Radiotherapy of refractory bone pain due to systemic mast cell disease. Am J Clin Oncol. 1994;17(4):328\u201330. https:\/\/doi.org\/10.1097\/00000421-199408000-00009.","journal-title":"Am J Clin Oncol"},{"issue":"Supplement 1","key":"901_CR56","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1182\/blood-2023-178927","volume":"142","author":"P Bose","year":"2023","unstructured":"Bose P, Oh ST, Modena B, Hunter AM, Akin C, Castells M, et al. Initial results from Summit: an Ongoing, 3-Part, Multi-center, Randomized, Double-Blind, placebo-controlled phase 2 clinical study of Bezuclastinib in Adult patients with Nonadvanced systemic mastocytosis (NonAdvSM). Blood. 2023;142(Supplement 1):77. https:\/\/doi.org\/10.1182\/blood-2023-178927.","journal-title":"Blood"},{"issue":"6","key":"901_CR57","doi-asserted-by":"publisher","first-page":"EVIDoa2200339","DOI":"10.1056\/EVIDoa2200339","volume":"2","author":"J Gotlib","year":"2023","unstructured":"Gotlib J, Castells M, Elberink HO, Siebenhaar F, Hartmann K, Broesby-Olsen S, et al. Avapritinib versus Placebo in Indolent systemic mastocytosis. NEJM Evid. 2023;2(6):EVIDoa2200339. https:\/\/doi.org\/10.1056\/EVIDoa2200339.","journal-title":"NEJM Evid"},{"issue":"Supplement 1","key":"901_CR58","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1182\/blood-2023-188904","volume":"142","author":"T Tashi","year":"2023","unstructured":"Tashi T, Hermine O, Castells M, Guilarte M, Sabato V, Maurer M, et al. Elenestinib, an investigational, next generation KIT D816V inhibitor, reduces mast cell Burden, improves symptoms, and has a Favorable Safety Profile in patients with indolent systemic mastocytosis: analysis of the Harbor Trial. Blood. 2023;142(Supplement 1):76. https:\/\/doi.org\/10.1182\/blood-2023-188904.","journal-title":"Blood"}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-025-00901-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11914-025-00901-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-025-00901-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:43:15Z","timestamp":1768473795000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11914-025-00901-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["901"],"URL":"https:\/\/doi.org\/10.1007\/s11914-025-00901-w","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,13]]},"assertion":[{"value":"21 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial Support and Sponsorship"}},{"value":"YD: research grant from Blueprint and Novartis, expertise for Amgen CN: none PA: none MM: none CBL: consultant and research grant from Blueprint Medicine, investigator for Blueprint Medicines, AB Science and Cogent ML: expertise for Amgen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"10"}}